1.
Safety and residue tests for the establishment of maximum residue limits (‘MRLs’) shall be carried out in conformity with the provisions related to Good Laboratory Practice (‘GLP’) as laid down in Directive 2004/10/EC of the European Parliament and of the Council. [Directive 2004/10/EC of the European Parliament and of the Council of 11 February 2004 on the harmonisation of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances (OJ L 50, 20.2.2004, p. 44).]
If data are available that have not been generated under GLP conditions, the potential impact of this shall be addressed.
2.
Use of experimental animals in safety and residue tests shall comply with Directive 2010/63/EU of the European Parliament and of the Council [Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes (OJ L 276, 20.10.2010, p. 33).].
3.
Documentation presented in relation to safety and residue tests shall name the laboratory where the work was performed and shall be signed and dated. Summaries of any studies that are not accompanied by the raw data shall not be accepted as valid documentation.
Design, methods and conduct of the studies, name and qualifications of investigator, place and period of time during which the study was undertaken shall be clear from the test reports. The experimental techniques shall be described in such detail as to allow them to be reproduced, and the investigator shall establish their validity. All abbreviations and codes, irrespective of whether they are internationally accepted or not, shall be accompanied by a key.
4.
Where applicable, all observed results from the studies submitted shall be evaluated by an appropriate statistical method and be discussed in conjunction with the other available studies. The results of all studies shall be presented in a form that facilitates their review.
5.
Test reports shall include the following information (where applicable):
chemical identification of the test pharmacologically active substance, including the isomer ratio and the enantiomers, if appropriate;
purity of the test substance;
formulation of the administered drug and method of dose preparation;
stability, including stability in vehicle and feed when so administered;
mode of dose administration (dose (expressed in mg/kg body weight), frequency of dosing, and duration of treatment);
for administration of the test substance other than in the diet or drinking water: the characteristics of the vehicle, including toxicological characteristics;
species, strain and source of test animals used, use of specific pathogen free animals, sex of the dosed animals, age of the animals at the beginning of the dosing, number of dosed animals;
dose levels and route and frequency of administration (with dosage in mg/kg bodyweight/day), test period, parameters followed, frequency of observation; conditions of animal husbandry including environmental conditions, water and food consumption (especially for drugs administered in drinking water and/or feed);
sampling time points;
description of toxic signs with the inclusion of time of onset, degree and duration (for safety tests), where appropriate;
results of the clinical observations, gross necropsy, histopathology and of all other parameters investigated (for safety tests), where appropriate;
where appropriate, an estimate of a no observed (adverse) effect level (‘NO(A)EL’) or lowest observed (adverse) effect level (‘LO(A)EL’) or lower bound of the benchmark dose (‘BMDL’) (for safety tests);
weight of dosed animals;
milk and egg production (if applicable);
specific activity and radio-purity of labelled substances (for residues tests);
sample collection, sample size, and sample storage;
analytical methods: a complete description of the procedure, including preparation of analytical samples, instrumentation and data derived from standards, control tissues, fortified tissues and tissues with incurred residues; validation data for the analytical method shall be provided, including limit of detection, limit of quantification, linearity in and around the relevant range of concentrations, stability, accuracy, precision and susceptibility to interferences;
raw data of all test results including those of the analytical method used to determine the residues in the edible tissues or products, methods of calculation.
6.
Biological substances other than those identified in Article 1(2)(a) of Regulation (EC) No 470/2009 of the European Parliament and of the Council [Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 152, 16.6.2009, p. 11).] shall be:
subject to a normal MRL where the biological substance is chemical-like insofar as it could be produced by chemical synthesis and so presents similar concerns to chemical substances and can be expected to leave residues in the same way as chemical substances (e.g. cytokines, hormones);
evaluated on a case-by-case basis where the biological substance is chemical-unlike insofar as being more complex than chemically synthesised pharmacologically active substances and so may contain multiple chemical types whose residues may generally be cells, amino acids, lipids, carbohydrates, nucleic acids and their breakdown products.
7.
For chemical-unlike biological substances, a report describing the scientific basis for the request on whether a full MRL evaluation is required or not shall be required together with the following information:
the nature of the biological substance (e.g. cell, tissue, live or killed organism) and a comparison with similar biological substances to which consumers are known to be routinely exposed;
a description of the mechanism of action underlying the substances therapeutic effect and, if available, information on its potency;
the fate of the substance in the treated animal (i.e. is it bioavailable, are residues expected in food commodities);
any activity that the substance may have in the human gut (are the residues inactive or do they produce local effects);
the systemic availability of residues following ingestion of residues by consumers, along with a worst case consumer exposure estimate.
The information provided above shall be evaluated in accordance with the guidance published by the European Medicines Agency (‘Agency’) in order to determine whether a ‘no MRL required’ classification according to the classification provided for under Article 14(2), point (c), of Regulation (EC) No 470/2009 is appropriate.
8.
Certain aspects of the data to be submitted in support of a MRL application for a substance for use in minor species or for minor uses may be reduced in comparison to the requirements for a substance that does not fall into this category. Evaluation shall be made based on the data requirements laid out in the Agency's ‘Guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market’ [Safety and residue data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001536.jsp&mid=WC0b01ac058002dd38).].
9.
The general principles for the derivation of MRLs for biocidal substances used in animal husbandry laid down in Article 10 of Regulation (EC) No 470/2009 shall be the same as for veterinary medicinal products.
1.
A full safety data package as described in this section shall be required for MRL evaluation for substances that have not previously been used in food-producing species.
2.
Where relevant and high quality literature data where all the details of the study are described are available, it may be possible to rely on these in place of a full study report commissioned by the applicant.
3.
If data are not provided for standard endpoints, thorough justification shall be required.
4.1.
A detailed and critical summary of the safety file shall be required.
4.2.
The detailed and critical summary shall:
include a clear position on the adequacy of the data presented, in light of current scientific knowledge;
have an introduction describing the actual or proposed pattern of use of the substance under review in animal husbandry and a summary of any other experience of its use;
consider the extent to which the substance concerned has similarities to other known substances, which may be relevant for the evaluation;
cover all standard data requirements, as set out in the Commission Implementing Regulation (EU) 2017/12 [Commission Implementing Regulation (EU) 2017/12 of 6 January 2017 regarding the form and content of the applications and requests for the establishment of maximum residue limits in accordance with Regulation (EC) No 470/2009 of the European Parliament and of the Council (OJ L 4, 7.1.2017, p. 1).], provide a critical evaluation of the available experimental studies and an interpretation of the results;
provide scientific justification for the omission of any studies that are described in this section;
discuss requirements for additional studies;
provide a description and explanation of the key findings for each study. The following issues shall be discussed: the animal species used, the number(s) of animals used, the route(s) of administration, the dosage(s), the duration of treatment, the exposure achieved, the dose response relationship, the nature of the adverse effects (their onset and duration, their dose dependency and reversibility and any species related or sex-related differences), known relevant structure-activity relationships and relevance of the findings for human consumers;
give a justification for the NO(A)EL or LO(A)EL or BMDL proposed for each study;
summarise and discuss relevant scientific literature, including reports of evaluations undertaken by other scientific bodies (such as the European Food Safety Authority (‘EFSA’), European Chemicals Agency (‘ECHA’) and the Joint Food and Agriculture Organisation (‘FAO’)/World Health Organisation (‘WHO’) Expert Committee on Food Additives (‘JECFA’)). If detailed references to published scientific literature are used, all the requirements set out under point I.5 shall be met, as far as possible;
include information on the quality of batches of test substances used in the safety studies. Any association between findings and the quality of the test substances and/or the medicinal products shall be indicated. When necessary, a critical evaluation of the impurities present in the active ingredient shall be presented and information on their potential biological effects shall be given. The implications of any differences of the chirality, chemical form and impurity profile between the substance used in the safety studies and the form to be marketed shall be discussed;
discuss the GLP status of the studies submitted;
discuss possible deficiencies in the design and conduct of the studies and their documentation, making reference to published Agency and other guidance. Any deviations from applicable guidance shall be highlighted and the impact of the deviation discussed and scientifically justified;
comment on the use of experimental animals in the studies and whether the studies were conducted in accordance with Directive 2010/63/EU;
provide a justification for the selection of critical NO(A)EL(s) or BMDL(s) and the derivation of the acceptable daily intake (‘ADI’), justifying the selection of uncertainty factors. If no ADI is proposed, or if an alternative toxicological reference value is selected, this shall be thoroughly justified.
4.3.
Annexes to the detailed and critical summary shall include:
list of references — a list of all references shall be provided in accordance with internationally accepted standards. The references themselves shall be included in the dossier;
tabulated study reports — tabular summaries of study reports. In addition, a complete set of study reports shall be included in the dossier.
5.1.
The data shall demonstrate that the substance has been precisely identified and characterised in order to ensure that the substance used in safety studies is reflective of the substance to be used in the field.
5.2.
Batches used in safety studies shall be identified and adequate specifications shall be provided, including purity (concentrations of impurities), isomer ratios and enantiomers, solubility and any other factor that may influence its activity.
5.3.
Information on the chemical and physicochemical properties of the substance may allow concerns to be identified and/or addressed based on known properties of substances with similar chemical and physicochemical properties.
6.1.1.
Data from the pharmacodynamic studies shall aim to enable the identification and characterisation of the mode/mechanisms of action that underlie the intended therapeutic effects as well as those underlying adverse effects/side effects. These studies shall be designed on a case-by-case basis taking account of available information with regard to the likely pharmacological actions for the substance.
6.1.2.
Particular consideration shall be given in relation to pharmacodynamic effects of the substance that may occur at doses below those required to produce toxicological effects, with consideration given to the need for derivation of a pharmacological ADI.
6.1.3.
Studies relevant to the establishment of a pharmacological ADI shall identify or characterise the mode of action, the dose-response relationship and identify a NOEL or BMDL, where possible and shall be used as a starting point from which a pharmacological ADI is derived. Where appropriate data are available from studies in humans (e.g. for substances with a history of use in human medicine) these shall usually be the most useful in identifying a pharmacological NOEL or BMDL. Guidance published by the Agency on the establishment of pharmacological ADI [Approach to establish a pharmacological acceptable daily intake (ADI) (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001530.jsp&mid=).] shall be followed.
6.1.4.
Data on the pharmacodynamic effects of a substance shall:
enable to identify/characterise the mode/mechanism of action of the substance;
enable characterisation of the dose-response relationship for relevant pharmacological endpoints;
provide insight into the potential toxic effects of the substance based on knowledge of known effects of other substances with similar pharmacodynamic properties;
aid the understanding of the mechanisms underlying adverse effects seen in toxicology studies;
provide, in certain cases, information on the relevance of effects seen in laboratory animals for humans.
6.1.5.
If pharmacodynamic data are not provided, their absence shall be scientifically justified and the impact of their absence discussed.
6.1.6.
If a pharmacological ADI is not derived, its absence shall be scientifically justified.
6.2.1.
Pharmacokinetic investigations shall provide information on the absorption of the substance, its distribution and persistence in the tissues, its metabolism and excretion. The oral route shall be the main route of administration in the pharmacokinetic studies as this is the route by which consumers are exposed.
6.2.2.
Metabolites produced in the laboratory animal species shall be compared to those seen in the target animal species, in line with the guidance provided in the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (‘VICH’) — VICH GL47: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: laboratory animal comparative metabolism studies [VICH GL47 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: laboratory animal comparative metabolism studies (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001515.jsp&mid=WC0b01ac058002dd37).].
6.2.3.
The pharmacokinetic data obtained from studies in laboratory animals shall be used to model the fate of the substance ingested by humans.
6.2.4.
Pharmacokinetic data in laboratory animals shall also be used to determine whether the metabolites that consumers will ingest in animal-derived food commodities are also produced in the laboratory animals used for safety testing. This is necessary in order to determine the relevance of the toxicological effects and NO(A)ELs or BMDLs obtained in the toxicology studies. If the laboratory animals produce the same metabolites to those produced by the food-producing animal, the laboratory animals shall be considered to have been auto-exposed to the metabolites that humans would consume. This is ordinarily taken as evidence that the safety of metabolites has been adequately assessed in the toxicology studies. If the metabolites produced by the target animal species are not produced in the laboratory animal studies, there may be a need to conduct safety studies using the major metabolite(s) produced in the target animal.
6.2.5.
Pharmacokinetic data may also help to explain unusual results obtained in toxicity studies, such as an apparent lack of dose-response when the drug is not well absorbed.
6.3.1.1.
Animal studies shall be performed by the oral route since this is the route of exposure for the consumer.
6.3.1.2.
Animal studies shall be conducted in established strains of laboratory animals for which historical data are available. Each substance shall be tested in the species and strain of animals that is the best model for its effects in humans.
6.3.1.3.
The substance to be tested shall be the active substance. However, if residues in foods derived from treated animals include significant amounts of a metabolite which is not produced in the laboratory animal species, the toxicity of the metabolite may need to be assessed separately.
6.3.1.4.
VICH GL33: Studies to evaluate the safety of residues of veterinary drugs in human food: general approach to testing [VICH GL33 Safety studies for veterinary drug residues in human food: general approach to testing (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001480.jsp&mid=WC0b01ac058002dd37).] shall be followed.
6.3.2.1.
Acute toxicity studies may have been performed for reasons other than the evaluation of consumer safety (e.g. for the evaluation of the user safety of a product) or may have been reported in published literature. Reports of any such studies shall be submitted as part of the Safety File.
6.3.2.2.
If available, acute toxicity data which may contribute to the overall picture of the toxicological profile of the substance and may highlight effects to look out for in longer term studies shall be provided.
6.3.3.1.1.
Data from repeat dose (90 day) oral toxicity studies shall be provided for both a rodent and a non-rodent species, together with the reasons for the choice of species, considering any available knowledge of the metabolism of the substance in animals and humans.
6.3.3.1.2.
Data from repeat dose oral toxicity testing studies shall:
allow the evaluation of the functional and morphological changes due to repeated administration of the test substance(s) and how these changes are related to dose;
allow the establishment of a NO(A)EL or LO(A)EL or BMDL;
inform the choice of dose levels for chronic studies as well as the choice of the most appropriate species for chronic studies.
6.3.3.1.3.
Guidance on the design of repeat dose (90-day) studies is provided in VICH GL31: Studies to evaluate the safety of residues of veterinary drugs in human food: repeat-dose (90 days) toxicity testing [VICH GL31 Safety studies for veterinary drug residues in human food: repeat-dose (90) toxicity testing (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001478.jsp&mid=WC0b01ac058002dd37).] and shall be followed. Any departures from established guidance shall be justified and the impact discussed.
6.3.3.1.4.
The absence of repeat dose (90-day) oral toxicity studies in rodents and/or non-rodents shall also be scientifically justified and the impact of their absence discussed.
6.3.3.2.1.
Chronic toxicity testing shall be conducted in at least one species. This shall be the most appropriate species chosen on the basis of all available scientific data, including the results of the 90-day studies, with the default species being the rat.
6.3.3.2.2.
The data from chronic oral toxicity testing studies shall allow:
the evaluation of the functional and morphological changes due to repeated administration of the test substance(s) and how these changes are related to dose;
the establishment of a NO(A)EL or LO(A)EL or BMDL.
6.3.3.2.3.
Guidance on the design of repeat dose (chronic) studies is provided in VICH GL37: Studies to evaluate the safety of residues of veterinary drugs in human food: repeat-dose (chronic) toxicity testing [VICH GL37 Safety of veterinary drugs in human food repeat-dose (chronic) toxicity testing (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001481.jsp&mid=WC0b01ac058002dd37).] and shall be followed. Any departures from established guidance shall be justified and the impact discussed.
6.3.3.2.4.
If a repeat dose (chronic) oral toxicity study is not provided, its absence shall be scientifically justified and the impact of its absence discussed.
6.3.4.1.
Data on tolerance in target species shall not be required for the evaluation of consumer safety. However, where relevant data have been generated or are reported in published literature, these shall be submitted as part of the Safety File.
6.3.4.2.
If available, data on tolerance in target species may contribute to the overall picture of the toxicological profile of the substance and may highlight effects to look out for in toxicity studies.
6.3.5.1.1.